Bellevue Group AG Boosts Position in Celldex Therapeutics, Inc. (NASDAQ:CLDX)

Bellevue Group AG raised its position in Celldex Therapeutics, Inc. (NASDAQ:CLDX) by 15.7% during the first quarter, according to the company in its most recent disclosure with the SEC. The firm owned 2,796,615 shares of the biopharmaceutical company’s stock after acquiring an additional 380,319 shares during the quarter. Celldex Therapeutics makes up 1.8% of Bellevue Group AG’s portfolio, making the stock its 16th biggest holding. Bellevue Group AG’s holdings in Celldex Therapeutics were worth $117,374,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also bought and sold shares of the company. Price T Rowe Associates Inc. MD increased its position in shares of Celldex Therapeutics by 631.1% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 3,087,208 shares of the biopharmaceutical company’s stock valued at $129,571,000 after purchasing an additional 2,664,915 shares during the last quarter. Magnetar Financial LLC bought a new stake in Celldex Therapeutics during the first quarter valued at approximately $452,000. Affinity Asset Advisors LLC increased its holdings in Celldex Therapeutics by 27.5% during the first quarter. Affinity Asset Advisors LLC now owns 510,000 shares of the biopharmaceutical company’s stock valued at $21,405,000 after buying an additional 110,000 shares during the last quarter. Natixis bought a new position in Celldex Therapeutics in the first quarter worth approximately $8,977,000. Finally, CANADA LIFE ASSURANCE Co boosted its stake in shares of Celldex Therapeutics by 26.4% during the 1st quarter. CANADA LIFE ASSURANCE Co now owns 4,570 shares of the biopharmaceutical company’s stock worth $192,000 after acquiring an additional 955 shares during the last quarter.

Analysts Set New Price Targets

CLDX has been the subject of several analyst reports. Cantor Fitzgerald restated an “overweight” rating and issued a $67.00 price objective on shares of Celldex Therapeutics in a research note on Tuesday, June 18th. Wolfe Research initiated coverage on Celldex Therapeutics in a report on Tuesday, June 11th. They set an “outperform” rating and a $51.00 price target for the company. HC Wainwright reaffirmed a “buy” rating and issued a $80.00 price objective on shares of Celldex Therapeutics in a research note on Tuesday, July 16th. Finally, Stifel Nicolaus assumed coverage on Celldex Therapeutics in a research report on Tuesday, June 18th. They set a “buy” rating and a $58.00 price objective on the stock. One equities research analyst has rated the stock with a hold rating and six have given a buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $62.17.

Insider Transactions at Celldex Therapeutics

In related news, SVP Margo Heath-Chiozzi sold 38,719 shares of the stock in a transaction that occurred on Thursday, May 30th. The stock was sold at an average price of $34.07, for a total transaction of $1,319,156.33. Following the completion of the transaction, the senior vice president now directly owns 7,094 shares of the company’s stock, valued at $241,692.58. The sale was disclosed in a filing with the SEC, which is available through this link. In related news, SVP Diane C. Young sold 45,000 shares of the business’s stock in a transaction on Friday, June 7th. The shares were sold at an average price of $35.26, for a total value of $1,586,700.00. Following the sale, the senior vice president now owns 2,115 shares in the company, valued at $74,574.90. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP Margo Heath-Chiozzi sold 38,719 shares of the company’s stock in a transaction on Thursday, May 30th. The shares were sold at an average price of $34.07, for a total transaction of $1,319,156.33. Following the sale, the senior vice president now directly owns 7,094 shares in the company, valued at approximately $241,692.58. The disclosure for this sale can be found here. Over the last three months, insiders have sold 266,332 shares of company stock valued at $9,155,821. 3.80% of the stock is currently owned by insiders.

Celldex Therapeutics Trading Up 1.6 %

Celldex Therapeutics stock traded up $0.70 during mid-day trading on Friday, hitting $44.56. The stock had a trading volume of 1,052,059 shares, compared to its average volume of 659,913. Celldex Therapeutics, Inc. has a one year low of $22.11 and a one year high of $53.18. The firm has a market capitalization of $2.94 billion, a P/E ratio of -15.64 and a beta of 1.58. The firm’s 50 day moving average is $36.66 and its 200 day moving average is $39.18.

Celldex Therapeutics (NASDAQ:CLDX) last released its quarterly earnings data on Monday, May 6th. The biopharmaceutical company reported ($0.56) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.67) by $0.11. The firm had revenue of $0.16 million for the quarter, compared to analysts’ expectations of $1.30 million. Celldex Therapeutics had a negative net margin of 2,385.57% and a negative return on equity of 29.55%. As a group, equities research analysts forecast that Celldex Therapeutics, Inc. will post -2.39 earnings per share for the current year.

About Celldex Therapeutics

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.